Bayer and Amgen's Onyx subsidiary announce an oncology drug failed a Phase-III trial goal among liver cancer patients.
Biogen Idec and Eisai said they will collaborate on and co-market two of Eisai's clinical candidates for Alzheimer's disease.
Kynamro's slow start, coupled with competition, has prompted Sanofi to add sales reps.
Bayer bought China-based Dihon Pharmaceutical Group, which specializes in traditional Chinese medicine consumer goods.
The drugmaker says the voluntary measure was out of an abundance of caution.
The agency says is it time to update the onerous decades-old review process.
Bloomberg reports that Teva has sparked interest as a takeover target.
Germany's price transparency requirement has the industry worried other markets will demand lower prices.
The drugmaker, hitherto known for its generic expertise, says the purchase could mean that half its future revenue will come from branded, specialty drugs.
Merck announced this week that its insulin glargine biosimilar, being developed with Samsung and Biogen Idec, would soon enter Phase-III trials.